ULTRALIFE CORP reported the first quarter ended March 31, 2026 results: revenue $47.4 million, net income ($0.5) million, EPS ($0.03) per basic and diluted share.
“First Quarter 2026 Financial Results Revenue was $47.4 million, a decrease of $3.3 million, or 6.5%, as compared to revenue of $50.7 million for the first quarter of 2025. Battery & Energy Products sales decreased 4.7% to $44.2 million compared to $46.3 million last year. The year-over-year decrease reflects a 5.5% decline in commercial sales due to lower oil & gas and industrial sales offsetting an increase in medical battery sales, and a 2.7% decline in government/defense sales due to the shipment of a very large order for an allied country last year. Communications Systems sales decreased by 25.7% to $3.3 million compared to $4.4 million for the same period last year, primarily attributable to the timing of expected orders. Our total backlog exiting the first quarter was $115.1 million, the highest level in the Company’s history, compared to $110.2 million exiting the fourth quarter of 2025 and $95.0 million exiting the first quarter of 2025. Gross profit was $10.1 million, or 21.3%”
Auditor Changes
ULTRALIFE CORP engaged Withum Smith+Brown, PC as its auditor.
“In connection with the Replacement, on August 22, 2025, the Committee approved the engagement of Withum as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, effective immediately.”
Auditor Changes
ULTRALIFE CORP dismissed Freed Maxick P.C. as its auditor.
“On August 22, 2025, the Audit and Finance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of Ultralife Corporation, Inc. (the “ Company ”) approved the replacement of Freed Maxick P.C. (“ FM ”) as the Company’s independent registered public accounting firm, due to the acquisition of certain assets of FM by Withum Smith+Brown, PC (“ Withum ”), effective immediately, and informed FM of such replacement on the date thereof (the “ Replacement ”).”
Earnings Releases
ULTRALIFE CORP reported financial results for first quarter ended March 31, 2024.
“On April 25, 2024, Ultralife Corporation issued a press release regarding the financial results for its first quarter ended March 31, 2024.”
Earnings Releases
ULTRALIFE CORP reported full year ended December 31, 2023 results: revenue $158.6 million, EPS Adjusted EPS of $0.52.
“representing a 134.8% year-over-year increase ● Backlog of $103.5 million exiting 2023, a 2.4% sequential increase over third quarter Fiscal Year 2023 Highlights: ● Sales of $158.6 million representing a 20.3% year-over-year increase ● Operating income of $9.5 million versus $0.1 million for 2022 ● Adjusted EPS of $0.52 compared to a loss of $0.07 for 2022 ●”
Earnings Releases
ULTRALIFE CORP reported fourth quarter ended December 31, 2023 results: revenue $44.5 million, net income $2.9 million, EPS $0.17 per diluted share.
“15, 2024 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: ● Sales of $44.5 million representing a 23.4% year-over-year increase ● Highest medical sales quarter in Company’s history ● Operating income of $3.6 million versus $0.2 million for the 2022 fourth”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.